福斯曼诺吉匹在急性髓系白血病伴中性粒细胞减少患者中的1b期静脉与口服给药安全性和药代动力学
这项开放标签、多中心1b期研究纳入21例接受缓解诱导化疗的急性髓系白血病伴中性粒细胞减少患者,10例接受静脉福斯曼诺吉匹600 mg每24小时一次,11例接受口服500 mg每24小时一次,共14天并随访28天。福斯曼诺吉匹相关不良事件26例次,无严重不良事件或导致停药者,安全性及药代动力学与健康志愿者相当。
要点
- 静脉600 mg与口服500 mg每24小时一次共14天,在急性髓系白血病伴中性粒细胞减少患者中安全且耐受良好。
- 福斯曼诺吉匹相关不良事件26例次,无严重不良事件或导致停药者。
- 口服与静脉剂量校正AUC几何均值比为95%,消除半衰期约2天。
核心结论
- 福斯曼诺吉匹在急性髓系白血病伴中性粒细胞减少并接受缓解诱导化疗的患者中安全且耐受良好。
- 其安全性和药代动力学特征与健康志愿者相当。
研究设计与样本
- 开放标签、多中心1b期研究,纳入21例接受缓解诱导化疗的成人急性髓系白血病患者。
- 10例接受静脉福斯曼诺吉匹600 mg每24小时一次,11例接受口服500 mg每24小时一次,给药14天,随访28天。
- 患者同时接受缓解诱导化疗[序贯高剂量阿糖胞苷和米托蒽醌(S-HAM)或7+3方案]及侵袭性真菌病预防(泊沙康唑)。
- 将既往健康志愿者研究建立的两室药代动力学模型拟合至manogepix血浆数据。
主要发现
- 9例(42.9%)患者发生26例次福斯曼诺吉匹相关不良事件[静脉:14例次;口服:12例次],其中静脉组5例(50%)、口服组4例(36.4%)。
- 无严重不良事件或导致福斯曼诺吉匹停药的不良事件。
- 最常见福斯曼诺吉匹相关不良事件为1/2级恶心[3例患者(14.3%)共4例次];呕吐、ALT升高和谵妄各[2例次;2例患者(9.5%)]。
- 1例患者发生福斯曼诺吉匹相关3级高血压。
- 口服与静脉剂量校正AUC几何均值比为95%;消除半衰期约2天,与既往健康志愿者研究一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Fosmanogepix (APX001), a first-in-class, intravenous (IV) and oral (PO) antifungal prodrug, is being developed to treat invasive fungal diseases (IFDs). Manogepix (APX001A; active moiety) targets fungal glycosylphosphatidylinositol-anchored cell wall transfer protein 1, inhibiting cell wall synthesis causing loss of viability. This open-label, multicentre, Phase 1b study in patients with AML and neutropenia (absolute neutrophil count <500 cells/μL; >10 days) undergoing chemotherapy aimed to assess tolerability, safety and pharmacokinetics (PK) of IV and PO fosmanogepix. METHODS: Of 21 adult AML patients undergoing remission induction chemotherapy, 10 received IV fosmanogepix (600 mg; q24h) and 11 received oral fosmanogepix (500 mg; q24h) over 14 days, with a 28 day follow-up. Patients also received remission induction chemotherapy [sequential high-dose cytarabine and mitoxantrone (S-HAM) or 7 + 3 regimen] for AML and IFD prophylaxis (posaconazole). A two-compartmental PK model from previous studies in healthy volunteers was fitted to manogepix plasma data. RESULTS: Of 26 fosmanogepix-related adverse events (AEs; IV: 14; PO: 12) in 9 (42.9%) patients [IV: 5 (50%); PO: 4 (36.4%)], none were serious or resulted in fosmanogepix discontinuation. Most frequently occurring fosmanogepix-related AEs were Grade 1/2 nausea [four events in three patients (14.3%)]; vomiting, ALT increase, and delirium [two events; two patients (9.5%) each]. One patient experienced fosmanogepix-related Grade 3 hypertension. Dose-corrected geometric mean ratio of AUC (PO-to-IV) was 95%. Elimination half-lives (∼2 days) were consistent with prior studies in healthy volunteers. CONCLUSIONS: Fosmanogepix was safe and well tolerated in AML patients with neutropenia receiving remission induction chemotherapy. Safety and PK profiles were comparable to healthy volunteers.
引用
- Cornely OA, Ostermann H, Koehler P, et al. Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia. J Antimicrob Chemother. 2023. PMID: 37681450. doi:10.1093/jac/dkad269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。